MyPhenome Test Earns Spot on TIME’s 2024 Best Inventions
Genetic test from Phenomix Sciences revolutionizes obesity treatment by uncovering the biology behind obesity through a simple saliva test.
Menlo Park, Calif. — October 30, 2024 – Phenomix Sciences, a precision medicine biotechnology company that brings data intelligence to obesity treatment, announces today its MyPhenome test has been recognized as one of TIME’s Best Inventions of 2024 in the medical care category. The MyPhenome test is a simple saliva swab that determines the root biological factors that can cause obesity and helps physicians personalize treatments for more effective weight loss. This annual list celebrates the top 200 innovations shaping the future, addressing critical challenges, and transforming lives across fields such as healthcare, AI, and green energy.
Developed based on decades of research at the Mayo Clinic, by Andres Acosta, M.D., Ph.D. and Michael Camilleri, M.D., the MyPhenome test enables patients to learn more about their biological makeup and physicians to match the right weight loss treatments to each patient based on their genetics, including lifestyle and diet intervention, as well as recommendations for medications like GLP-1s and/or procedures. Studies have shown obesity treatments tailored to a patient’s biological traits and identified through the MyPhenome test are twice as effective as other one-size-fits-all treatments.
“We’re making major strides to eliminate the guesswork in obesity treatment and help bring real, science-backed weight loss solutions to patients struggling with this disease,” said Mark Bagnall, CEO, of Phenomix Sciences. “Weight loss is complex, and it’s time we give patients and providers the tools they need to finally understand the unique factors driving their health. Being named among so many groundbreaking inventions highlights the potential for the MyPhenome test to make a profound impact on the lives of millions facing the global obesity epidemic.”
Phenomix Sciences is funded and supported by key partners, including Health2047, DexCom, Inc. and Labcorp.
“Equipping physicians with cutting-edge tools and insights aimed at addressing a health condition that affects millions globally is why we worked hand in hand with the Phenomix team to build this company,” said Larry Cohen, CEO of Health2047, a venture studio founded by the American Medical Association.
TIME evaluated nominations based on originality, impact, and efficacy, selecting the MyPhenome test as one of 2024’s most promising innovations in healthcare. The full TIME Best Inventions list for 2024 is available at time.com/best-inventions-2024.
Visit myphenometest.com to order the MyPhenome test or find a clinic offering the test near you. To find out more about Phenomix Sciences and supporting research, click here.
About Phenomix Sciences
Phenomix Sciences is a precision obesity biotechnology company on a mission to conquer obesity globally through the use of our proprietary genetic tests, unique data sets and advanced analytics. Phenomix believes that the key to understanding obesity is its unprecedented access to clinical and molecular information throughout all stages and phenotypes of the disease. Phenomix leverages data intelligence to yield better accuracy in predicting individual patient response to specific weight loss interventions and reducing the variability in weight loss results for patients. For more information, please visit www.phenomixsciences.com.
###
Media Contact:
